{"gene":"BRD9","run_date":"2026-04-28T17:12:38","timeline":{"discoveries":[{"year":2018,"finding":"BRD9 is a bromodomain-containing subunit of the SWI/SNF chromatin remodeling complex BAF, and its bromodomain can be targeted by VHL-based PROTAC degraders (VZ185) that redirect E3 ubiquitin ligase activity to selectively degrade BRD9 within cells.","method":"PROTAC degrader design, ternary complex formation thermodynamics, cellular ubiquitination assays, kinetic profiling","journal":"Journal of medicinal chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstituted ternary complex biochemistry, cellular ubiquitination assays, structure-guided optimization, replicated across two PROTAC series","pmids":["30540463"],"is_preprint":false},{"year":2017,"finding":"BRD9 bromodomain can be targeted by cereblon E3 ubiquitin ligase-recruiting heterobifunctional degraders (dBRD9), achieving 10- to 100-fold enhanced potency over parental BRD9 bromodomain ligands in AML models.","method":"Heterobifunctional PROTAC design, cellular degradation assays, MS proteomics","journal":"Angewandte Chemie (International ed. in English)","confidence":"High","confidence_rationale":"Tier 1–2 — iterative chemical design with cellular validation, MS confirmation of degradation selectivity","pmids":["28418626"],"is_preprint":false},{"year":2015,"finding":"BRD9 contains a bromodomain that functions as an acetyl-lysine reader; I-BRD9 is a selective inhibitor (>700-fold selectivity over BET family, >200-fold over BRD7) identified by structure-based design that displaces BRD9 from chromatin and regulates oncology and immune response gene networks.","method":"Structure-based drug design, selectivity profiling across bromodomain panel, cellular chromatin displacement assays, gene expression profiling in Kasumi-1 cells","journal":"Journal of medicinal chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — crystal structure-guided design, validated with functional cellular assays and broad selectivity panel","pmids":["25856009"],"is_preprint":false},{"year":2018,"finding":"BRD9 defines a non-canonical BAF complex (GBAF) in mouse embryonic stem cells together with GLTSCR1 or GLTSCR1L, which is distinct from the canonical esBAF complex; GBAF co-localizes with regulators of naive pluripotency and BRD9 interacts with BRD4 in a bromodomain-dependent fashion to recruit GBAF to chromatin.","method":"Co-immunoprecipitation, ChIP-seq, genome-wide localization, inhibitor treatments, pluripotency functional assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP, genome-wide ChIP-seq, bromodomain-dependent interaction validated pharmacologically","pmids":["30510198"],"is_preprint":false},{"year":2019,"finding":"BRD9 defines a SWI/SNF sub-complex lacking SMARCB1; SMARCB1 loss causes increased BRD9 incorporation into SWI/SNF; while BRD9's bromodomain is dispensable, its DUF3512 domain is essential for SWI/SNF complex integrity in the absence of SMARCB1, creating a specific vulnerability in SMARCB1-mutant rhabdoid tumors.","method":"Genome-wide CRISPR-Cas9 screen, domain deletion/mutation analysis, ChIP-seq, co-immunoprecipitation","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 — genome-wide CRISPR screen, domain mutagenesis, ChIP-seq, Co-IP with multiple orthogonal methods","pmids":["31015438"],"is_preprint":false},{"year":2016,"finding":"BRD9, as a subunit of the SWI-SNF chromatin remodeling complex, is required in AML cells to sustain MYC transcription; a bromodomain-swap resistance allele of BRD9 retains SWI/SNF functionality despite altered bromodomain pocket, establishing on-target BRD9 bromodomain engagement as the antiproliferative mechanism.","method":"Bromodomain-swap genetic engineering (allelic replacement), small-molecule inhibitor series, antiproliferative assays, MYC transcription measurement","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 1–2 — engineered resistance allele confirms on-target mechanism, combined with chemical probe and differentiation assays","pmids":["27376689"],"is_preprint":false},{"year":2020,"finding":"Following DNA damage, the BRD9 bromodomain binds acetylated K515 on RAD54 and facilitates RAD54's interaction with RAD51, which is essential for homologous recombination (HR)-mediated DNA double-strand break repair.","method":"Co-immunoprecipitation, pulldown assays, HR reporter assays, BRD9 inhibitor (I-BRD9) treatment, RAD54 acetylation mapping","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — specific acetyl-lysine binding identified, Co-IP of BRD9-RAD54-RAD51 complex, functional HR assays, replicated with inhibitor and genetic depletion","pmids":["32457312"],"is_preprint":false},{"year":2020,"finding":"BRD9 interacts with androgen receptor (AR) and CTCF, and the GBAF (ncBAF) complex exhibits overlapping genome localization with BET proteins to coordinate SWI/SNF-BET cooperation in AR-dependent gene expression in prostate cancer.","method":"Co-immunoprecipitation, ChIP-seq, BRD9 inhibitor/degrader treatment, xenograft tumor growth assays","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — Co-IP of BRD9 with AR and CTCF, ChIP-seq genome localization overlap, functional loss-of-function with defined transcriptional phenotype","pmids":["33355184"],"is_preprint":false},{"year":2022,"finding":"BRD9, as a subunit of the ncBAF complex, regulates interferon-stimulated genes (ISGs) in macrophages; BRD9 and BRD4 are cobound at ISG promoters and co-recruited upon endotoxin stimulation along with STAT1, STAT2, and IRF9 (ISGF3 complex); BRD9 inhibition or degradation reduces STAT1/STAT2/IRF9 binding at these loci.","method":"ChIP-seq, BRD9 inhibitor (BRD9i) and degrader (dBRD9) treatment, gene expression analysis, transcription factor binding assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — ChIP-seq genome-wide with orthogonal pharmacological and degrader approaches, STAT factor binding quantified","pmids":["34983841"],"is_preprint":false},{"year":2021,"finding":"BRD9 colocalizes with GR at a subset of genomic binding sites in macrophages; depletion of BRD9 enhances GR occupancy at inflammatory-related genes, thereby potentiating GR-induced transcriptional repression, identifying BRD9 as a genomic antagonist of GR.","method":"ChIP-seq, BRD9 inhibition, degradation, and genetic deletion in macrophages, GR occupancy analysis, inflammatory gene expression profiling","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — genome-wide ChIP-seq with multiple orthogonal BRD9 depletion methods, in vivo validation in HFD mouse model","pmids":["34446564"],"is_preprint":false},{"year":2015,"finding":"Binding of a 9H-purine scaffold ligand to the BRD9 bromodomain causes an unprecedented rearrangement of residues forming the acetyllysine recognition site (induced-fit pocket), and displaces BRD9 from chromatin without affecting BRD4/histone complexes.","method":"Crystal structure determination, bioluminescence proximity assay, structure-based iterative design","journal":"Journal of medicinal chemistry","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with induced-fit mechanism validated by functional chromatin displacement assay","pmids":["25703523"],"is_preprint":false},{"year":2019,"finding":"BRD9 binds enhancer regions in a cell-type-specific manner in AML cells and sustains a STAT5 signaling pathway by regulating SOCS3 expression levels, which is required for leukemia cell survival.","method":"ChIP-seq, siRNA knockdown, gene expression profiling, apoptosis assays in AML cells and primary blasts","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP-seq localization data with functional loss-of-function; single lab","pmids":["31000698"],"is_preprint":false},{"year":2021,"finding":"In clear cell RCC, SOX17 recruits BRD9 to de novo super enhancers associated with oncogenic genes (CCND1, VEGFR2, CDC20, SRC, MAPK6); BRD9 mRNA is stabilized via FTO-mediated m6A demethylation in HIF2α-low ccRCC.","method":"CRISPR-Cas9 knockout screen in vivo, RNA-seq, ChIP-seq, m6A analysis","journal":"Science translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 — CRISPR screen plus ChIP-seq plus RNA-seq; SOX17-BRD9 recruitment shown by ChIP but direct interaction not biochemically confirmed","pmids":["34586831"],"is_preprint":false},{"year":2023,"finding":"BRD9 forms a complex with SMAD2/3, BRD4, β-CATENIN, and P300 to regulate TGF-β/Nodal/Activin and Wnt signaling pathways by controlling H3K27ac deposition on pluripotency and differentiation genes in human ESCs.","method":"Co-immunoprecipitation, ChIP-seq, H3K27ac profiling, BRD9 depletion/inhibition, rescue experiments with pathway ligands","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP of multi-protein complex, ChIP-seq, functional epistasis with pathway ligand rescue; single lab","pmids":["37870468"],"is_preprint":false},{"year":2023,"finding":"BRD9 inhibition disrupts enhancer-promoter looping and transcription of stemness genes in pancreatic cancer stem-like cells, and mechanistically cooperates with TGF-β/Activin-SMAD2/3 signaling to orchestrate CSC stemness.","method":"Small molecule epigenetic screen, genetic ablation, 3D chromatin looping analysis, patient-derived xenografts","journal":"Gastroenterology","confidence":"Medium","confidence_rationale":"Tier 2 — chromatin looping assays, genetic ablation, PDX models; single lab","pmids":["37739089"],"is_preprint":false},{"year":2019,"finding":"CCAR2 acetylation by sulforaphane creates a binding site recognized by BRD9 (and BET family members); BRD9 acts as an acetyl reader of acetylated CCAR2, revealed by protein domain arrays and pull-down assays, contributing to a BET/BRD9 acetyl switch governing Wnt coactivator functions.","method":"Protein domain arrays, pull-down assays, Co-IP, BRD9 inhibitor treatment (JQ1/sulforaphane combination), colorectal cancer model","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 3 — pulldown and domain array identification of acetyl-reader function; supported by phenotypic data in vivo","pmids":["30643017"],"is_preprint":false},{"year":2023,"finding":"BRD9 interacts with transcription factor FOXP1, activating Stat1 transcription and IFN-β signaling, thereby suppressing osteoclastogenesis through a negative feedback mechanism on RANKL-induced osteoclast differentiation.","method":"Co-immunoprecipitation, ChIP assays, myeloid-specific Brd9 conditional knockout mouse model, osteoclast differentiation assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — Co-IP of BRD9-FOXP1, ChIP at Stat1 locus, in vivo conditional KO with bone phenotype, multiple orthogonal methods","pmids":["36918560"],"is_preprint":false},{"year":2023,"finding":"BRD9 loss in hematopoietic stem cells enhances chromatin accessibility and significantly colocalizes with CTCF; BRD9 loss augments CTCF chromatin recruitment, leading to altered chromatin state and expression of myeloid-related genes within intact topologically associating domains.","method":"ChIP-seq, ATAC-seq, RNA-seq, Hi-C, conditional Brd9 knockout mouse model","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 — multi-omics (ChIP-seq, ATAC-seq, Hi-C), in vivo KO with defined hematopoietic phenotypes","pmids":["38102116"],"is_preprint":false},{"year":2022,"finding":"BRD9 inhibition downregulates fibroblast-related genes and decreases chromatin accessibility at somatic enhancers during human cell reprogramming; BRD9 maintains expression of transcriptional regulators MN1 and ZBTB38 that impede reprogramming, acting as a barrier to pluripotency.","method":"Genetic and chemical inhibition of BRD9, ATAC-seq, gene expression profiling, reprogramming efficiency assays","journal":"Stem cell reports","confidence":"Medium","confidence_rationale":"Tier 2 — ATAC-seq and functional reprogramming assays; single lab, specific downstream targets identified","pmids":["36332631"],"is_preprint":false},{"year":2025,"finding":"BRD9 plays a pivotal role in recruiting BRD2 and BRD4 to chromatin through direct interactions, preventing R-loop formation during transcription; BRD9 depletion reduces BRD2/BRD4 occupancy at R-loop-prone sites, promoting R-loop accumulation, transcription-replication conflict, and DNA damage in leukemia cells.","method":"Co-immunoprecipitation, ChIP-seq, R-loop detection (DRIP-seq), PROTAC-based BRD9 degradation, proliferation and differentiation assays","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 — direct BRD9-BRD2/BRD4 interaction by Co-IP, R-loop mapping genome-wide, multiple depletion strategies with convergent phenotypes","pmids":["40613709"],"is_preprint":false},{"year":2025,"finding":"BRD9 functions as a reader of methylated arginine-391 (R391) of AKT1 through an aromatic cage in its bromodomain, unexpectedly extending its reader function beyond acetyl-lysine; BRD9 and AKT co-regulate transcription through EZH2-mediated H3K27 methylation.","method":"Biochemical binding assays, bromodomain mutational analysis, RNA-seq, in vivo tumor growth assays, synergy assays with EZH2 inhibitors","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 1–2 — novel reader function identified with direct binding assays, aromatic cage mutagenesis, functional downstream validation","pmids":["40279411"],"is_preprint":false},{"year":2025,"finding":"BRD9 binds to HIV-1 LTR promoter and competes with HIV-1 Tat protein for binding to the HIV-1 genome, functioning as an HIV-1 latency regulator; BRD9 inhibition synergizes with BRD4 inhibition in inducing HIV-1 production.","method":"CUT&RUN DNA sequencing, transcriptomics, BRD9 inhibition/knockdown/degradation in T cell lines and primary CD4+ T cells, competition binding assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 — CUT&RUN mapping of BRD9 at LTR, competition with Tat, multiple BRD9 depletion strategies; single lab","pmids":["40402245"],"is_preprint":false},{"year":2022,"finding":"Ultra-rare truncating loss-of-function variants in BRD9 impair IFN-stimulated gene expression and antiviral activity, establishing BRD9 as functionally required for full type I interferon signaling; full-length BRD9 but not truncated forms restore IFN-dependent antiviral response.","method":"BRD9 knockout and reconstitution model, functional IFN-stimulated gene expression assays, viral replication assays","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 — reconstitution of KO cells with wild-type vs. truncated variants, functional antiviral readout; single lab","pmids":["36100643"],"is_preprint":false},{"year":2022,"finding":"BRD9 epigenetically coordinates H3K27ac modifications on promoter regions of glycolysis genes ENO2 and ALDOC, inducing enhanced glycolysis activity in colon adenocarcinoma cells.","method":"ChIP assay for H3K27ac at ENO2/ALDOC promoters, Seahorse metabolic flux analysis, BRD9 knockdown/overexpression, in vivo xenograft model","journal":"Cancer medicine","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP-qPCR for H3K27ac at specific loci, metabolic functional assays; single lab","pmids":["35778964"],"is_preprint":false},{"year":2025,"finding":"BRD9 inhibits p53 nuclear translocation via direct binding, subsequently activating E2F transcription factors; E2F1 directly binds and transactivates the BRD9 promoter, establishing a positive BRD9-p53-E2F1 feedback loop in gastric cancer.","method":"Co-immunoprecipitation, subcellular fractionation, luciferase reporter assays, RNA sequencing","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP of BRD9-p53, fractionation showing p53 nuclear exclusion, luciferase reporter for E2F1-BRD9 promoter interaction; single lab","pmids":["41039535"],"is_preprint":false},{"year":2024,"finding":"BRD9 ncBAF complex regulates AML transcription through H3K27ac sensing by BRD9 bromodomain; BRD9 bromodomain activity maintains chromatin accessibility at gene promoters and distal enhancers at GATA, ETS, and AP-1 motifs, repressing myeloid maturation factors and tumor suppressor genes.","method":"BRD9 bromodomain inhibition, nascent transcription assays (TT-seq), ATAC-seq, CUT&RUN, in five AML cell lines","journal":"Cancer research communications","confidence":"Medium","confidence_rationale":"Tier 2 — multi-omics approach in multiple AML cell lines; bromodomain-specific inhibition separates reader from scaffold function","pmids":["38126767"],"is_preprint":false},{"year":2025,"finding":"BRD9 selectively recruits DCAF16 E3 ligase via a reversible covalent interaction at DCAF16 Cys58, facilitated by ternary complex formation with BRD9, enabling targeted protein degradation (molecular glue mechanism); BRD9 degradation is achieved in vivo after oral dosing.","method":"Co-immunoprecipitation-mass spectrometry, mutagenesis of DCAF16 Cys58, ternary complex analysis, in vivo xenograft mouse model with oral dosing","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 — Co-IP-MS confirming selective DCAF16 recruitment, cysteine mutagenesis validation, in vivo proof of concept","pmids":["41145412"],"is_preprint":false},{"year":2025,"finding":"BRD9 loss in SF3B1-mutant hematopoiesis enhances CTCF occupancy at the ALOX5 locus boundary via aberrant chromatin loop formation (revealed by Hi-C), driving transcriptional activation of ALOX5 and increased lipid peroxidation/ferroptosis susceptibility.","method":"RNA-seq, ChIP-seq, Hi-C, BODIPY-C11 lipid peroxidation assay, BRD9 depletion mouse models","journal":"International journal of hematology","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP-seq plus Hi-C mechanistic link, functional ferroptosis assay; single lab","pmids":["41219678"],"is_preprint":false},{"year":2026,"finding":"BRD9's bromodomain reads lactate-induced H3K18 lactylation (H3K18la) with transient affinity through its conserved acetyl-lysine pocket (distinct from stable H3K18ac binding), dynamically recruiting ncBAF to active enhancers/promoters to drive oncogenic transcription in hepatocellular carcinoma.","method":"NMR structural analysis, biophysical binding assays, multi-omics (ATAC-seq, ChIP-seq, RNA-seq), BRD9 targeting experiments in HCC","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 1 — NMR structural characterization of H3K18la binding plus multi-omics functional validation; novel PTM reader activity","pmids":["41792243"],"is_preprint":false},{"year":2025,"finding":"PPARα interacts with ncBAF via BRD9; BRD9 negatively regulates PPARα-mediated transactivation of fatty acid oxidation genes (including CPT1A) by restricting chromatin accessibility at PPRE elements; BRD9 inhibition enhances PPARα binding to CPT1A PPRE.","method":"Glycerol sedimentation assay, co-immunoprecipitation, pull-down assays, ChIP-qPCR, FAIRE-qPCR, BRD9 inhibitor (BI-9564) treatment in HepG2 and primary hepatocytes, in vivo mouse model","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1–2 — direct PPARα-BRD9 interaction by Co-IP and pulldown, ChIP and FAIRE chromatin accessibility assays, in vivo lipid phenotype","pmids":["40780491"],"is_preprint":false},{"year":2025,"finding":"BRD9 binds RELA and potentiates expression of downstream antiviral genes in glioblastoma, creating resistance to oncolytic herpes simplex virus; BRD9 knockout or inhibition suppresses antiviral gene expression and enhances oncolytic virus efficacy.","method":"CRISPR screening, co-immunoprecipitation (BRD9-RELA), transcriptomic analysis, in vitro and in vivo GBM models","journal":"Cell reports. Medicine","confidence":"Medium","confidence_rationale":"Tier 2 — CRISPR screen plus Co-IP of BRD9-RELA, functional oncolytic virus assay; single lab","pmids":["40744020"],"is_preprint":false},{"year":2024,"finding":"BRD9 interacts with FOXP1 to regulate CST1 expression and downstream PI3K/AKT signaling in gallbladder cancer, as demonstrated by ChIP-qPCR showing BRD9 occupancy at CST1 promoter and co-interaction with FOXP1.","method":"siRNA knockdown, ChIP-qPCR, RNA sequencing, in vivo xenograft model, FOXP1-BRD9 interaction assay","journal":"Gene therapy","confidence":"Medium","confidence_rationale":"Tier 3 — ChIP-qPCR at specific locus and FOXP1 interaction; single lab, limited mechanistic depth","pmids":["39306629"],"is_preprint":false},{"year":2019,"finding":"BRD9 is found in the SWI/SNF complex bound to the MYC super-enhancer locus in PIK3CA/KRAS double-mutant breast epithelial cells; small molecule inhibition of BRD9 reduces MYC transcript levels and anchorage-independent growth dependent on BRD9 expression.","method":"ChIP at MYC super-enhancer, CRISPR-Cas9 BRD9 manipulation, BRD9 inhibitor treatment, anchorage-independent growth assays","journal":"Cancers","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP at MYC enhancer, genetic CRISPR validation, functional epistasis with PIK3CA; single lab","pmids":["31652979"],"is_preprint":false},{"year":2024,"finding":"BRD9 promotes MYC target gene expression in multiple myeloma by predominantly occupying promoter regions of ribosome biogenesis genes and cooperating with BRD4 to enhance MYC transcriptional function.","method":"shRNA knockdown, PROTAC degrader (dBRD9-A), ChIP-seq at ribosome biogenesis gene promoters, RNA-seq, in vivo xenograft","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP-seq occupancy data, genetic and pharmacological depletion; BRD9-BRD4 cooperation at MYC targets supported but BRD4 interaction not directly biochemically shown","pmids":["36780189"],"is_preprint":false},{"year":2022,"finding":"Pharmacological BRD9 inhibition in macrophages disrupts BRD9 and SMARCA4 occupancy at melanocyte-specific chromatin loci, repressing pigmentation-specific gene expression and melanin synthesis.","method":"ChIP assays for BRD9 and SMARCA4, iBRD9 treatment, BRD9 depletion, gene expression profiling in melanoblasts and melanocytes","journal":"Pigment cell & melanoma research","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP showing BRD9/SMARCA4 co-occupancy at melanocyte loci, confirmed by genetic depletion; single lab","pmids":["36112085"],"is_preprint":false}],"current_model":"BRD9 is the defining bromodomain-containing subunit of the non-canonical BAF (ncBAF/GBAF) SWI/SNF chromatin remodeling complex, where its bromodomain reads acetylated lysines (and unexpectedly methylated arginine and lactylated lysine) on histones and non-histone proteins to recruit ncBAF to chromatin; its DUF3512 domain is essential for complex integrity, while it interacts with BRD4, CTCF, SMAD2/3, androgen receptor, GR, p53, FOXP1, RAD54, RELA, and PPARα to regulate gene expression programs controlling pluripotency, hematopoiesis, immune responses, DNA repair via homologous recombination, and oncogenic transcription in multiple cancer contexts."},"narrative":{"teleology":[{"year":2015,"claim":"Establishing that BRD9 contains a druggable acetyl-lysine-reading bromodomain with unique structural plasticity resolved whether this domain could be selectively targeted apart from the closely related BRD7 and BET family members.","evidence":"Crystal structures of BRD9 bromodomain with ligands revealed an induced-fit rearrangement of the acetyl-lysine pocket, and I-BRD9 achieved >700-fold selectivity over BET and >200-fold over BRD7, displacing BRD9 from chromatin in Kasumi-1 AML cells","pmids":["25703523","25856009"],"confidence":"High","gaps":["No histone mark specificity defined at this stage","Cellular targets of BRD9 bromodomain beyond generic chromatin association unknown"]},{"year":2016,"claim":"Demonstrating that BRD9's bromodomain engagement sustains MYC transcription in AML cells established the first functional requirement for BRD9 reader activity in an oncogenic transcriptional program.","evidence":"Bromodomain-swap resistance allele in AML cells confirmed that antiproliferative effects of BRD9 inhibitors are on-target and linked to MYC transcript downregulation","pmids":["27376689"],"confidence":"High","gaps":["Which SWI/SNF sub-complex BRD9 belongs to was not yet defined","Mechanism by which BRD9 is recruited to MYC locus not resolved"]},{"year":2018,"claim":"Identifying BRD9 as the defining subunit of a non-canonical BAF complex (ncBAF/GBAF) containing GLTSCR1/GLTSCR1L resolved the composition of a previously uncharacterized SWI/SNF variant and revealed its BRD4-dependent chromatin recruitment at naive pluripotency loci.","evidence":"Reciprocal Co-IP, ChIP-seq, and bromodomain inhibitor treatments in mouse ESCs showed GBAF is distinct from esBAF; BRD9 interacts with BRD4 in a bromodomain-dependent manner","pmids":["30510198"],"confidence":"High","gaps":["Whether BRD9-BRD4 interaction is direct or mediated through shared chromatin marks","Structural basis of GLTSCR1 incorporation into ncBAF"]},{"year":2019,"claim":"Establishing that the DUF3512 domain (not the bromodomain) is essential for SWI/SNF complex integrity in SMARCB1-mutant cancers revealed a synthetic lethal vulnerability and separated BRD9's scaffolding from its reader function.","evidence":"CRISPR screen and domain deletion analysis in rhabdoid tumor cells showed SMARCB1 loss increases BRD9 incorporation and creates BRD9 dependency through DUF3512","pmids":["31015438"],"confidence":"High","gaps":["Structural basis of DUF3512-mediated complex assembly unknown","Whether DUF3512 dependency extends to other SMARCB1-deficient tumor types"]},{"year":2019,"claim":"Demonstrating BRD9 as an acetyl-reader of non-histone substrates (CCAR2) broadened its recognition repertoire beyond histone tails and implicated it in Wnt coactivator regulation.","evidence":"Protein domain arrays and pull-down assays showed BRD9 bromodomain binds acetylated CCAR2, contributing to a BET/BRD9 acetyl switch in colorectal cancer","pmids":["30643017"],"confidence":"Medium","gaps":["Direct binding affinity not quantified","Specificity of BRD9 versus BET recognition of CCAR2 acetylation unclear"]},{"year":2020,"claim":"Identifying BRD9 as a reader of acetylated RAD54 that facilitates RAD54-RAD51 interaction established a direct role for BRD9 in homologous recombination DNA repair, independent of its canonical chromatin remodeling function.","evidence":"Co-IP, pulldown, and HR reporter assays showed BRD9 bromodomain binds RAD54 K515ac and is required for RAD54-RAD51 complex formation after DNA damage","pmids":["32457312"],"confidence":"High","gaps":["Whether BRD9-RAD54 interaction occurs in the context of ncBAF or as a free subunit","No structural model of BRD9-RAD54 interaction"]},{"year":2020,"claim":"Showing that BRD9/ncBAF interacts with androgen receptor and CTCF and co-localizes with BET proteins genome-wide in prostate cancer linked ncBAF to steroid hormone-driven transcription.","evidence":"Co-IP of BRD9 with AR and CTCF, ChIP-seq overlap with BET, and BRD9 degrader/inhibitor treatment reducing AR target gene expression and xenograft tumor growth","pmids":["33355184"],"confidence":"High","gaps":["Whether BRD9 directly bridges AR and BRD4 or they are independently recruited","Contribution of CTCF to BRD9-AR cooperation not dissected"]},{"year":2021,"claim":"Demonstrating that BRD9 depletion enhances GR occupancy at inflammatory gene loci established BRD9 as a genomic antagonist of glucocorticoid receptor, revealing a competition model for transcription factor access at shared sites.","evidence":"ChIP-seq with BRD9 inhibition/degradation/knockout in macrophages showed increased GR binding at inflammatory genes; validated in vivo in high-fat diet mouse model","pmids":["34446564"],"confidence":"High","gaps":["Whether BRD9-GR antagonism is direct or mediated through chromatin state changes","Mechanism by which ncBAF limits GR accessibility not resolved"]},{"year":2022,"claim":"Establishing that BRD9 and BRD4 are co-recruited to ISG promoters with ISGF3 upon endotoxin stimulation, and that BRD9 loss reduces STAT1/2/IRF9 binding, defined BRD9 as a chromatin prerequisite for interferon-stimulated gene activation in innate immunity.","evidence":"ChIP-seq in macrophages with BRD9 inhibitor and dBRD9 degrader showed diminished ISGF3 component occupancy at ISG loci; complemented by truncation variants failing to rescue IFN responses","pmids":["34983841","36100643"],"confidence":"High","gaps":["Whether BRD9 directly recruits ISGF3 or remodels chromatin to permit ISGF3 binding","Contribution of ncBAF ATPase activity versus BRD9 reader activity not separated"]},{"year":2023,"claim":"Identifying BRD9 in a complex with SMAD2/3, BRD4, β-catenin, and P300 at pluripotency genes, and showing BRD9 mediates enhancer-promoter looping for stemness genes, unified its roles in TGF-β/Wnt signaling and 3D chromatin architecture.","evidence":"Co-IP of multi-protein complex in hESCs, ChIP-seq for H3K27ac, rescue with pathway ligands; chromatin looping analysis in pancreatic cancer stem cells","pmids":["37870468","37739089"],"confidence":"Medium","gaps":["Stoichiometry of the BRD9-SMAD2/3-BRD4-P300 complex not defined","Whether BRD9 directly mediates looping or acts indirectly through cohesin/CTCF"]},{"year":2023,"claim":"Demonstrating that BRD9 loss in hematopoietic stem cells increases CTCF chromatin occupancy and alters chromatin architecture within TADs revealed BRD9 as a modulator of 3D genome organization controlling myeloid differentiation.","evidence":"Multi-omics (ChIP-seq, ATAC-seq, Hi-C, RNA-seq) in conditional Brd9 knockout mice showed enhanced CTCF binding and myeloid gene activation","pmids":["38102116"],"confidence":"High","gaps":["How ncBAF mechanistically limits CTCF occupancy (direct competition vs. nucleosome positioning)","Whether altered TAD structure is a cause or consequence of differentiation changes"]},{"year":2025,"claim":"Discovering that BRD9 reads methylated arginine on AKT1 (R391me) through an aromatic cage in its bromodomain fundamentally expanded the recognition code beyond acetyl-lysine to include arginine methylation marks.","evidence":"Biochemical binding assays and aromatic cage mutagenesis showed direct BRD9 bromodomain binding to AKT1 R391me; functional cooperation with EZH2-mediated H3K27me shown by synergy assays","pmids":["40279411"],"confidence":"High","gaps":["Structural basis of arginine methylation reading versus acetyl-lysine reading not resolved at atomic level","Breadth of methylarginine substrates recognized by BRD9 unknown"]},{"year":2025,"claim":"Showing that BRD9 recruits BRD2/BRD4 to chromatin and prevents R-loop accumulation at transcription-replication conflict sites established a genome stability function beyond homologous recombination.","evidence":"Co-IP, ChIP-seq, and DRIP-seq in leukemia cells showed BRD9 depletion reduces BRD2/BRD4 occupancy at R-loop-prone sites, causing R-loop accumulation and DNA damage","pmids":["40613709"],"confidence":"High","gaps":["Whether R-loop resolution requires ncBAF ATPase activity or only BRD9-BET recruitment","No reconstituted system demonstrating BRD9-dependent R-loop prevention"]},{"year":2026,"claim":"Identifying lactylated H3K18 (H3K18la) as a physiologically relevant mark read by BRD9's bromodomain with transient affinity expanded the epigenetic reader code to include metabolic signaling through lactate-driven histone modification.","evidence":"NMR structural analysis showed H3K18la binds the conserved acetyl-lysine pocket with lower affinity than H3K18ac; multi-omics in hepatocellular carcinoma confirmed dynamic ncBAF recruitment to lactylation-marked enhancers","pmids":["41792243"],"confidence":"High","gaps":["Whether transient H3K18la reading confers distinct transcriptional kinetics compared to stable H3K18ac reading","In vivo validation of lactylation-dependent BRD9 recruitment in non-cancer contexts"]},{"year":null,"claim":"The structural basis of how BRD9's bromodomain discriminates among acetylated, methylated, and lactylated marks, and how the DUF3512 domain scaffolds the ncBAF complex, remain unresolved at atomic resolution.","evidence":"","pmids":[],"confidence":"High","gaps":["No full-length BRD9 structure or cryo-EM structure of BRD9 within ncBAF","Mechanism by which BRD9 limits CTCF occupancy not biochemically reconstituted","Whether BRD9's non-histone reader functions operate within or outside the ncBAF complex context"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[2,6,10,15,20,25,28]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[9,24,29]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[5,8,13,16,23]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[3,4,7,8,17,25]},{"term_id":"GO:0005694","term_label":"chromosome","supporting_discovery_ids":[3,4,17,19,25,28]}],"pathway":[{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[3,4,17,25,28]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[5,8,13,16,23,29]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[6,19]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[8,9,22,30]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[11,13,14,24,29]}],"complexes":["ncBAF (GBAF) SWI/SNF complex"],"partners":["BRD4","CTCF","SMARCA4","GLTSCR1","RAD54","FOXP1","RELA","PPARA"],"other_free_text":[]},"mechanistic_narrative":"BRD9 is the defining bromodomain-containing subunit of the non-canonical BAF (ncBAF/GBAF) chromatin remodeling complex, where it functions as a multivalent epigenetic reader that recruits SWI/SNF remodeling activity to specific genomic loci in a context-dependent manner to regulate gene expression programs governing pluripotency, hematopoiesis, immune signaling, DNA repair, and metabolism. Its bromodomain reads acetylated lysines on histones (H3K27ac, H3K18ac) and non-histone proteins (RAD54 K515ac, CCAR2), and also recognizes methylated arginine (AKT1 R391me) and lactylated lysine (H3K18la), while its DUF3512 domain is essential for ncBAF complex integrity [PMID:30510198, PMID:31015438, PMID:32457312, PMID:40279411, PMID:41792243]. BRD9 physically interacts with BRD4 and BRD2 to coordinate BET-SWI/SNF cooperation at promoters and enhancers, and partners with transcription factors including CTCF, androgen receptor, GR, SMAD2/3, FOXP1, RELA, PPARα, and p53 to direct locus-specific chromatin accessibility and transcriptional output [PMID:33355184, PMID:34983841, PMID:34446564, PMID:36918560, PMID:37870468, PMID:40780491, PMID:40613709]. BRD9 loss increases CTCF chromatin occupancy and alters three-dimensional chromatin architecture within topologically associating domains, and disrupts R-loop resolution at transcription-replication conflict sites, linking its function to genome stability and myeloid differentiation [PMID:38102116, PMID:40613709, PMID:41219678]."},"prefetch_data":{"uniprot":{"accession":"Q9H8M2","full_name":"Bromodomain-containing protein 9","aliases":["Rhabdomyosarcoma antigen MU-RMS-40.8"],"length_aa":597,"mass_kda":67.0,"function":"Plays a role in chromatin remodeling and regulation of transcription (PubMed:22464331, PubMed:26365797). Acts as a chromatin reader that recognizes and binds acylated histones: binds histones that are acetylated and/or butyrylated (PubMed:26365797). Component of SWI/SNF chromatin remodeling subcomplex GBAF that carries out key enzymatic activities, changing chromatin structure by altering DNA-histone contacts within a nucleosome in an ATP-dependent manner (PubMed:29374058). Also orchestrates the RAD51-RAD54 complex formation and thereby plays a role in homologous recombination (HR) (PubMed:32457312)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q9H8M2/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BRD9","classification":"Not Classified","n_dependent_lines":43,"n_total_lines":1208,"dependency_fraction":0.03559602649006623},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"SMARCA4","stoichiometry":4.0},{"gene":"SMARCD1","stoichiometry":4.0},{"gene":"SMARCC1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/BRD9","total_profiled":1310},"omim":[{"mim_id":"618502","title":"BRD4-INTERACTING CHROMATIN REMODELING COMPLEX-ASSOCIATED PROTEIN-LIKE; BICRAL","url":"https://www.omim.org/entry/618502"},{"mim_id":"618465","title":"BROMODOMAIN-CONTAINING PROTEIN 9; BRD9","url":"https://www.omim.org/entry/618465"},{"mim_id":"605690","title":"BRD4-INTERACTING CHROMATIN REMODELING COMPLEX-ASSOCIATED PROTEIN; BICRA","url":"https://www.omim.org/entry/605690"},{"mim_id":"605590","title":"SPLICING FACTOR 3B, SUBUNIT 1; SF3B1","url":"https://www.omim.org/entry/605590"},{"mim_id":"313650","title":"TAF1 RNA POLYMERASE II, TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR, 250-KD; TAF1","url":"https://www.omim.org/entry/313650"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/BRD9"},"hgnc":{"alias_symbol":["FLJ13441","SMARCI2"],"prev_symbol":[]},"alphafold":{"accession":"Q9H8M2","domains":[{"cath_id":"1.20.920.10","chopping":"141-244","consensus_level":"high","plddt":94.9392,"start":141,"end":244},{"cath_id":"-","chopping":"322-360","consensus_level":"medium","plddt":62.5746,"start":322,"end":360},{"cath_id":"-","chopping":"399-465","consensus_level":"high","plddt":82.6964,"start":399,"end":465}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H8M2","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H8M2-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H8M2-F1-predicted_aligned_error_v6.png","plddt_mean":62.97},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BRD9","jax_strain_url":"https://www.jax.org/strain/search?query=BRD9"},"sequence":{"accession":"Q9H8M2","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9H8M2.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9H8M2/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H8M2"}},"corpus_meta":[{"pmid":"30540463","id":"PMC_30540463","title":"Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel-Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7.","date":"2018","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30540463","citation_count":250,"is_preprint":false},{"pmid":"28418626","id":"PMC_28418626","title":"Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands.","date":"2017","source":"Angewandte Chemie (International ed. in English)","url":"https://pubmed.ncbi.nlm.nih.gov/28418626","citation_count":220,"is_preprint":false},{"pmid":"25856009","id":"PMC_25856009","title":"Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition.","date":"2015","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25856009","citation_count":186,"is_preprint":false},{"pmid":"30510198","id":"PMC_30510198","title":"A non-canonical BRD9-containing BAF chromatin remodeling complex regulates naive pluripotency in mouse embryonic stem cells.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30510198","citation_count":174,"is_preprint":false},{"pmid":"31015438","id":"PMC_31015438","title":"BRD9 defines a SWI/SNF sub-complex and constitutes a specific vulnerability in malignant rhabdoid tumors.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31015438","citation_count":167,"is_preprint":false},{"pmid":"27376689","id":"PMC_27376689","title":"Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition.","date":"2016","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/27376689","citation_count":156,"is_preprint":false},{"pmid":"30660651","id":"PMC_30660651","title":"miR-140-3p functions as a tumor suppressor in squamous cell lung cancer by regulating BRD9.","date":"2019","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/30660651","citation_count":73,"is_preprint":false},{"pmid":"33355184","id":"PMC_33355184","title":"BRD9 Is a Critical Regulator of Androgen Receptor Signaling and Prostate Cancer Progression.","date":"2020","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/33355184","citation_count":63,"is_preprint":false},{"pmid":"32457312","id":"PMC_32457312","title":"The bromodomain containing protein BRD-9 orchestrates RAD51-RAD54 complex formation and regulates homologous recombination-mediated repair.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32457312","citation_count":61,"is_preprint":false},{"pmid":"34586831","id":"PMC_34586831","title":"Aberrant activation of m6A demethylase FTO renders HIF2αlow/- clear cell renal cell carcinoma sensitive to BRD9 inhibitors.","date":"2021","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34586831","citation_count":57,"is_preprint":false},{"pmid":"31000698","id":"PMC_31000698","title":"BRD9 binds cell type-specific chromatin regions regulating leukemic cell survival via STAT5 inhibition.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31000698","citation_count":53,"is_preprint":false},{"pmid":"25703523","id":"PMC_25703523","title":"9H-purine scaffold reveals induced-fit pocket plasticity of the BRD9 bromodomain.","date":"2015","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25703523","citation_count":51,"is_preprint":false},{"pmid":"31000582","id":"PMC_31000582","title":"GSK2801, a BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast Cancer.","date":"2019","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/31000582","citation_count":49,"is_preprint":false},{"pmid":"28714904","id":"PMC_28714904","title":"BRD9 Inhibition, Alone or in Combination with Cytostatic Compounds as a Therapeutic Approach in Rhabdoid Tumors.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28714904","citation_count":48,"is_preprint":false},{"pmid":"35853853","id":"PMC_35853853","title":"BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma.","date":"2022","source":"Blood cancer journal","url":"https://pubmed.ncbi.nlm.nih.gov/35853853","citation_count":42,"is_preprint":false},{"pmid":"36918560","id":"PMC_36918560","title":"BRD9-mediated chromatin remodeling suppresses osteoclastogenesis through negative feedback mechanism.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36918560","citation_count":40,"is_preprint":false},{"pmid":"34983841","id":"PMC_34983841","title":"BRD9 regulates interferon-stimulated genes during macrophage activation via cooperation with BET protein BRD4.","date":"2022","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/34983841","citation_count":39,"is_preprint":false},{"pmid":"33380808","id":"PMC_33380808","title":"Targeting BRD9 for Cancer Treatment: A New Strategy.","date":"2020","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33380808","citation_count":35,"is_preprint":false},{"pmid":"34885774","id":"PMC_34885774","title":"Insights into the Ligand Binding to Bromodomain-Containing Protein 9 (BRD9): A Guide to the Selection of Potential Binders by Computational Methods.","date":"2021","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/34885774","citation_count":34,"is_preprint":false},{"pmid":"34446564","id":"PMC_34446564","title":"Bromodomain containing 9 (BRD9) regulates macrophage inflammatory responses by potentiating glucocorticoid receptor activity.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/34446564","citation_count":33,"is_preprint":false},{"pmid":"38102116","id":"PMC_38102116","title":"BRD9 determines the cell fate of hematopoietic stem cells by regulating chromatin state.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38102116","citation_count":32,"is_preprint":false},{"pmid":"32410449","id":"PMC_32410449","title":"Application of Atypical Acetyl-lysine Methyl Mimetics in the Development of Selective Inhibitors of the Bromodomain-Containing Protein 7 (BRD7)/Bromodomain-Containing Protein 9 (BRD9) Bromodomains.","date":"2020","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32410449","citation_count":32,"is_preprint":false},{"pmid":"30643017","id":"PMC_30643017","title":"Acetylation of CCAR2 Establishes a BET/BRD9 Acetyl Switch in Response to Combined Deacetylase and Bromodomain Inhibition.","date":"2019","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/30643017","citation_count":31,"is_preprint":false},{"pmid":"36780189","id":"PMC_36780189","title":"BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma.","date":"2023","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/36780189","citation_count":28,"is_preprint":false},{"pmid":"30225973","id":"PMC_30225973","title":"Insight into selective mechanism of class of I-BRD9 inhibitors toward BRD9 based on molecular dynamics simulations.","date":"2018","source":"Chemical biology & drug design","url":"https://pubmed.ncbi.nlm.nih.gov/30225973","citation_count":27,"is_preprint":false},{"pmid":"31652979","id":"PMC_31652979","title":"PIK3CA Cooperates with KRAS to Promote MYC Activity and Tumorigenesis via the Bromodomain Protein BRD9.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31652979","citation_count":26,"is_preprint":false},{"pmid":"34771678","id":"PMC_34771678","title":"The BRD9/7 Inhibitor TP-472 Blocks Melanoma Tumor Growth by Suppressing ECM-Mediated Oncogenic Signaling and Inducing Apoptosis.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34771678","citation_count":26,"is_preprint":false},{"pmid":"37739089","id":"PMC_37739089","title":"BRD9-SMAD2/3 Orchestrates Stemness and Tumorigenesis in Pancreatic Ductal Adenocarcinoma.","date":"2023","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/37739089","citation_count":23,"is_preprint":false},{"pmid":"36801999","id":"PMC_36801999","title":"BRD9 Inhibition Attenuates Matrix Degradation and Pyroptosis in Nucleus Pulposus by Modulating the NOX1/ROS/NF-κB axis.","date":"2023","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/36801999","citation_count":23,"is_preprint":false},{"pmid":"37870468","id":"PMC_37870468","title":"BRD9-mediated control of the TGF-β/Activin/Nodal pathway regulates self-renewal and differentiation of human embryonic stem cells and progression of cancer cells.","date":"2023","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/37870468","citation_count":22,"is_preprint":false},{"pmid":"35116642","id":"PMC_35116642","title":"Targeting BRD9 by I-BRD9 efficiently inhibits growth of acute myeloid leukemia cells.","date":"2021","source":"Translational cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/35116642","citation_count":19,"is_preprint":false},{"pmid":"35778964","id":"PMC_35778964","title":"BRD9 is an essential regulator of glycolysis that creates an epigenetic vulnerability in colon adenocarcinoma.","date":"2022","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35778964","citation_count":19,"is_preprint":false},{"pmid":"36709803","id":"PMC_36709803","title":"Epigenetic modulation by targeting bromodomain containing protein 9 (BRD9): Its therapeutic potential and selective inhibition.","date":"2023","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/36709803","citation_count":17,"is_preprint":false},{"pmid":"34667163","id":"PMC_34667163","title":"BRD9 inhibition promotes PUMA-dependent apoptosis and augments the effect of imatinib in gastrointestinal stromal tumors.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/34667163","citation_count":16,"is_preprint":false},{"pmid":"39132814","id":"PMC_39132814","title":"Discovery of CW-3308 as a Potent, Selective, and Orally Efficacious PROTAC Degrader of BRD9.","date":"2024","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39132814","citation_count":16,"is_preprint":false},{"pmid":"39413023","id":"PMC_39413023","title":"Programmed BRD9 Degradation and Hedgehog Signaling Activation via Silk-Based Core-Shell Microneedles Promote Diabetic Wound Healing.","date":"2024","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/39413023","citation_count":15,"is_preprint":false},{"pmid":"38913763","id":"PMC_38913763","title":"Discovery of a Highly Potent and Selective BRD9 PROTAC Degrader Based on E3 Binder Investigation for the Treatment of Hematological Tumors.","date":"2024","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38913763","citation_count":15,"is_preprint":false},{"pmid":"36332631","id":"PMC_36332631","title":"BRD9-containing non-canonical BAF complex maintains somatic cell transcriptome and acts as a barrier to human reprogramming.","date":"2022","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/36332631","citation_count":14,"is_preprint":false},{"pmid":"36577218","id":"PMC_36577218","title":"Identification of 2,4,5-trisubstituted-2,4-dihydro-3H-1,2,4-triazol-3-one-based small molecules as selective BRD9 binders.","date":"2022","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36577218","citation_count":14,"is_preprint":false},{"pmid":"39491427","id":"PMC_39491427","title":"Structure-based identification of new orally bioavailable BRD9-PROTACs for treating acute myelocytic leukemia.","date":"2023","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39491427","citation_count":13,"is_preprint":false},{"pmid":"38126767","id":"PMC_38126767","title":"The ncBAF Complex Regulates Transcription in AML Through H3K27ac Sensing by BRD9.","date":"2024","source":"Cancer research communications","url":"https://pubmed.ncbi.nlm.nih.gov/38126767","citation_count":13,"is_preprint":false},{"pmid":"37352721","id":"PMC_37352721","title":"Exploring the chemical space of functionalized [1,2,4]triazolo[4,3-a]quinoxaline-based compounds targeting the bromodomain of BRD9.","date":"2023","source":"Bioorganic chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37352721","citation_count":13,"is_preprint":false},{"pmid":"34823196","id":"PMC_34823196","title":"Introducing structure-based three-dimensional pharmacophore models for accelerating the discovery of selective BRD9 binders.","date":"2021","source":"Bioorganic chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34823196","citation_count":13,"is_preprint":false},{"pmid":"27769361","id":"PMC_27769361","title":"Development of chemical probes for the bromodomains of BRD7 and BRD9.","date":"2016","source":"Drug discovery today. Technologies","url":"https://pubmed.ncbi.nlm.nih.gov/27769361","citation_count":12,"is_preprint":false},{"pmid":"36297001","id":"PMC_36297001","title":"BRD9 Inhibition by Natural Polyphenols Targets DNA Damage/Repair and Apoptosis in Human Colon Cancer Cells.","date":"2022","source":"Nutrients","url":"https://pubmed.ncbi.nlm.nih.gov/36297001","citation_count":11,"is_preprint":false},{"pmid":"27120693","id":"PMC_27120693","title":"An Advanced Tool To Interrogate BRD9.","date":"2016","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27120693","citation_count":11,"is_preprint":false},{"pmid":"35678942","id":"PMC_35678942","title":"Circ_CSPP1 Regulates the Development of Non-small Cell Lung Cancer via the miR-486-3p/BRD9 Axis.","date":"2022","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35678942","citation_count":10,"is_preprint":false},{"pmid":"38543178","id":"PMC_38543178","title":"Identification and Development of BRD9 Chemical Probes.","date":"2024","source":"Pharmaceuticals (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/38543178","citation_count":9,"is_preprint":false},{"pmid":"36362300","id":"PMC_36362300","title":"Identification of Selective BRD9 Inhibitor via Integrated Computational Approach.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36362300","citation_count":9,"is_preprint":false},{"pmid":"39306629","id":"PMC_39306629","title":"BRD9 promotes the progression of gallbladder cancer via CST1 upregulation and interaction with FOXP1 through the PI3K/AKT pathway and represents a therapeutic target.","date":"2024","source":"Gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/39306629","citation_count":9,"is_preprint":false},{"pmid":"30058436","id":"PMC_30058436","title":"Molecular mechanism study of several inhibitors binding to BRD9 bromodomain based on molecular simulations.","date":"2018","source":"Journal of biomolecular structure & dynamics","url":"https://pubmed.ncbi.nlm.nih.gov/30058436","citation_count":9,"is_preprint":false},{"pmid":"38610997","id":"PMC_38610997","title":"Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple Myeloma.","date":"2024","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/38610997","citation_count":8,"is_preprint":false},{"pmid":"34944438","id":"PMC_34944438","title":"Exploring the Value of BRD9 as a Biomarker, Therapeutic Target and Co-Target in Prostate Cancer.","date":"2021","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/34944438","citation_count":8,"is_preprint":false},{"pmid":"40960846","id":"PMC_40960846","title":"Discovery of BRD9 Molecular Glue Degraders That Spare Cardiomyocytes.","date":"2025","source":"Journal of the American Chemical Society","url":"https://pubmed.ncbi.nlm.nih.gov/40960846","citation_count":7,"is_preprint":false},{"pmid":"35117701","id":"PMC_35117701","title":"BRD9 controls the oxytocin signaling pathway in gastric cancer via CANA2D4, CALML6, GNAO1, and KCNJ5.","date":"2020","source":"Translational cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/35117701","citation_count":7,"is_preprint":false},{"pmid":"36112085","id":"PMC_36112085","title":"Epigenetic and pharmacological control of pigmentation via Bromodomain Protein 9 (BRD9).","date":"2022","source":"Pigment cell & melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/36112085","citation_count":6,"is_preprint":false},{"pmid":"30824168","id":"PMC_30824168","title":"Design, synthesis and biological evaluation of imidazo[1,5-a]pyrazin-8(7H)-one derivatives as BRD9 inhibitors.","date":"2019","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30824168","citation_count":6,"is_preprint":false},{"pmid":"40109374","id":"PMC_40109374","title":"In-depth functional analysis of BRD9 in fetal hematopoiesis reveals context-dependent roles.","date":"2025","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/40109374","citation_count":5,"is_preprint":false},{"pmid":"41145412","id":"PMC_41145412","title":"Mode of action of a DCAF16-recruiting targeted glue that can selectively degrade BRD9.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/41145412","citation_count":5,"is_preprint":false},{"pmid":"38971334","id":"PMC_38971334","title":"BI-7273, a BRD9 inhibitor, reduces lipid accumulation by downregulating the AKT/mTOR/SREBP1 signaling pathway.","date":"2024","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38971334","citation_count":5,"is_preprint":false},{"pmid":"40263302","id":"PMC_40263302","title":"Prostate cancer exploits BRD9-driven metabolic reprogramming to shape the aggressive phenotype.","date":"2025","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/40263302","citation_count":4,"is_preprint":false},{"pmid":"36100643","id":"PMC_36100643","title":"Ultra-Rare BRD9 Loss-of-Function Variants Limit the Antiviral Action of Interferon.","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/36100643","citation_count":4,"is_preprint":false},{"pmid":"38070581","id":"PMC_38070581","title":"BRD9 status is a major contributor for cysteine metabolic remodeling through MST and EAAT3 modulation in malignant melanoma.","date":"2023","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/38070581","citation_count":4,"is_preprint":false},{"pmid":"38816579","id":"PMC_38816579","title":"BRD9 regulates normal human hematopoietic stem cell function and lineage differentiation.","date":"2024","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/38816579","citation_count":3,"is_preprint":false},{"pmid":"40167526","id":"PMC_40167526","title":"BRD9 inhibition as potential treatment option for testicular germ cell tumors.","date":"2025","source":"Andrology","url":"https://pubmed.ncbi.nlm.nih.gov/40167526","citation_count":3,"is_preprint":false},{"pmid":"39124901","id":"PMC_39124901","title":"Unveiling Allosteric Regulation and Binding Mechanism of BRD9 through Molecular Dynamics Simulations and Markov Modeling.","date":"2024","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/39124901","citation_count":3,"is_preprint":false},{"pmid":"41285423","id":"PMC_41285423","title":"Discovery of CFT8634, a Potent, Selective, and Orally Bioavailable Heterobifunctional Degrader of BRD9.","date":"2025","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/41285423","citation_count":3,"is_preprint":false},{"pmid":"41033607","id":"PMC_41033607","title":"STAT3 induced BRD9 activation promotes intrahepatic cholangiocarcinoma progression by enhancing CD36 controlled fatty acid metabolism.","date":"2025","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/41033607","citation_count":2,"is_preprint":false},{"pmid":"40402245","id":"PMC_40402245","title":"BRD9 functions as an HIV-1 latency regulatory factor.","date":"2025","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/40402245","citation_count":2,"is_preprint":false},{"pmid":"40744020","id":"PMC_40744020","title":"BRD9 inhibition overcomes oncolytic virus therapy resistance in glioblastoma.","date":"2025","source":"Cell reports. Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/40744020","citation_count":2,"is_preprint":false},{"pmid":"39903580","id":"PMC_39903580","title":"BRD9 promotes the malignant phenotype of thyroid cancer by activating the MAPK/ERK pathway.","date":"2025","source":"Anti-cancer drugs","url":"https://pubmed.ncbi.nlm.nih.gov/39903580","citation_count":2,"is_preprint":false},{"pmid":"40343767","id":"PMC_40343767","title":"Unveiling New Triazoloquinoxaline-Based PROTACs Designed for the Selective Degradation of the ncBAF Chromatin Remodeling Subunit BRD9.","date":"2025","source":"Chemistry (Weinheim an der Bergstrasse, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/40343767","citation_count":2,"is_preprint":false},{"pmid":"39119716","id":"PMC_39119716","title":"In Silico Design, Chemical Synthesis, Biophysical and in Vitro Evaluation for the Identification of 1-Ethyl-1H-Pyrazolo[3,4-b]Pyridine-Based BRD9 Binders.","date":"2024","source":"ChemPlusChem","url":"https://pubmed.ncbi.nlm.nih.gov/39119716","citation_count":2,"is_preprint":false},{"pmid":"40613709","id":"PMC_40613709","title":"Depletion of BRD9-mediated R-loop accumulation inhibits leukemia cell growth via transcription-replication conflict.","date":"2025","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/40613709","citation_count":1,"is_preprint":false},{"pmid":"41039535","id":"PMC_41039535","title":"BRD9-p53-E2F1 circuit orchestrates cell growth and DNA damage repair in gastric cancer.","date":"2025","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/41039535","citation_count":1,"is_preprint":false},{"pmid":"40279411","id":"PMC_40279411","title":"BRD9 functions as a methylarginine reader to regulate AKT-EZH2 signaling.","date":"2025","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/40279411","citation_count":1,"is_preprint":false},{"pmid":"38972607","id":"PMC_38972607","title":"TPPP-BRD9 fusion-related gallbladder carcinomas are frequently associated with intracholecystic neoplasia, neuroendocrine carcinoma, and a distinctive small tubular-type adenocarcinoma commonly accompanied with a syringomatous pattern.","date":"2024","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/38972607","citation_count":1,"is_preprint":false},{"pmid":"40176372","id":"PMC_40176372","title":"Brd9 antagonism induces beige adipocytes in white adipose tissues and protects against diet-induced obesity.","date":"2025","source":"Obesity (Silver Spring, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/40176372","citation_count":1,"is_preprint":false},{"pmid":"41477332","id":"PMC_41477332","title":"Key imidazolyl groups that induce phenylalanine flipping enhance the efficacy of oral BRD9 inhibitors for AML treatment.","date":"2025","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/41477332","citation_count":1,"is_preprint":false},{"pmid":"41219678","id":"PMC_41219678","title":"BRD9 depletion-mediated ALOX5 upregulation via chromatin dysregulation induces ferroptosis in SF3B1-mutant hematopoiesis.","date":"2025","source":"International journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/41219678","citation_count":1,"is_preprint":false},{"pmid":"36909530","id":"PMC_36909530","title":"BRD9-SMAD2/3 orchestrates stemness and tumorigenesis in pancreatic ductal adenocarcinoma.","date":"2023","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/36909530","citation_count":0,"is_preprint":false},{"pmid":"41672512","id":"PMC_41672512","title":"BRD9 at the crossroads of splicing, chromatin remodeling, and hematopoiesis.","date":"2026","source":"Proceedings of the Japan Academy. Series B, Physical and biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/41672512","citation_count":0,"is_preprint":false},{"pmid":"41326797","id":"PMC_41326797","title":"Integrative analysis reveals synergistic regulation of Sp7 by BRD9 and Wnt/β-catenin signaling during osteogenic differentiation.","date":"2025","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/41326797","citation_count":0,"is_preprint":false},{"pmid":"41440042","id":"PMC_41440042","title":"SS18::SSX and BRD9 Modulate Synovial Sarcoma Differentiation.","date":"2025","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/41440042","citation_count":0,"is_preprint":false},{"pmid":"41797932","id":"PMC_41797932","title":"The dual role of BRD9 in cancer: Mechanistic insights and therapeutic prospects.","date":"2026","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/41797932","citation_count":0,"is_preprint":false},{"pmid":"40780491","id":"PMC_40780491","title":"Chromatin remodeler BRD9 represses transcription of PPARα target genes, including CPT1A to suppress lipid metabolism.","date":"2025","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/40780491","citation_count":0,"is_preprint":false},{"pmid":"41409030","id":"PMC_41409030","title":"The future of BRD9 inhibitors: a patent perspective (2019-present).","date":"2025","source":"Expert opinion on therapeutic patents","url":"https://pubmed.ncbi.nlm.nih.gov/41409030","citation_count":0,"is_preprint":false},{"pmid":"41792243","id":"PMC_41792243","title":"BRD9 recognizes lactate-induced H3K18 lactylation to drive oncogenic chromatin remodeling in hepatocellular carcinoma.","date":"2026","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/41792243","citation_count":0,"is_preprint":false},{"pmid":"41943612","id":"PMC_41943612","title":"Virtual screening and cellular validation of dolutegravir as a BRD9 inhibitor for attenuating pyroptosis in peritoneal mesothelial cells.","date":"2026","source":"Renal failure","url":"https://pubmed.ncbi.nlm.nih.gov/41943612","citation_count":0,"is_preprint":false},{"pmid":"41752361","id":"PMC_41752361","title":"A 5-Br-1-Propylisatin Derivative as a Promising BRD9 Ligand: Insights from Computational and STD NMR Investigation.","date":"2026","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/41752361","citation_count":0,"is_preprint":false},{"pmid":"41980921","id":"PMC_41980921","title":"Aberrant activation of epigenetic BRD9-DGAT1 axis promotes lipid droplets deposition and ferroptosis resistance in YAP-high prostate cancer.","date":"2026","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/41980921","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.04.12.648552","title":"The PBAF chromatin remodeling complex contributes to metal homeostasis through Mtf1 regulation","date":"2025-04-13","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.12.648552","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.12.31.630899","title":"Selective degradation of BRD9 by a DCAF16-recruiting targeted glue: mode of  action elucidation and in vivo proof of concept","date":"2025-01-02","source":"bioRxiv","url":"https://doi.org/10.1101/2024.12.31.630899","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.12.09.627499","title":"Discovery of molecular glues that bind FKBP12 and novel targets using DNA-barcoded libraries","date":"2024-12-12","source":"bioRxiv","url":"https://doi.org/10.1101/2024.12.09.627499","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.02.10.637448","title":"Development of a BiAD sensor for locus-specific detection of cellular histone acetylation dynamics by fluorescence microscopy","date":"2025-02-12","source":"bioRxiv","url":"https://doi.org/10.1101/2025.02.10.637448","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.02.03.636343","title":"Accurate PROTAC targeted degradation prediction with DegradeMaster","date":"2025-02-07","source":"bioRxiv","url":"https://doi.org/10.1101/2025.02.03.636343","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.02.26.640292","title":"Virus-host interactome reveals host cellular pathways perturbed by tick-borne encephalitis virus infection","date":"2025-02-26","source":"bioRxiv","url":"https://doi.org/10.1101/2025.02.26.640292","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.12.23.630090","title":"YDS-GlueFold: Surpassing AlphaFold 3-Type Models for Molecular Glue-Induced Ternary Complex Prediction","date":"2024-12-23","source":"bioRxiv","url":"https://doi.org/10.1101/2024.12.23.630090","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48211,"output_tokens":8115,"usd":0.133179},"stage2":{"model":"claude-opus-4-6","input_tokens":11937,"output_tokens":4140,"usd":0.244778},"total_usd":0.377957,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2018,\n      \"finding\": \"BRD9 is a bromodomain-containing subunit of the SWI/SNF chromatin remodeling complex BAF, and its bromodomain can be targeted by VHL-based PROTAC degraders (VZ185) that redirect E3 ubiquitin ligase activity to selectively degrade BRD9 within cells.\",\n      \"method\": \"PROTAC degrader design, ternary complex formation thermodynamics, cellular ubiquitination assays, kinetic profiling\",\n      \"journal\": \"Journal of medicinal chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted ternary complex biochemistry, cellular ubiquitination assays, structure-guided optimization, replicated across two PROTAC series\",\n      \"pmids\": [\"30540463\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"BRD9 bromodomain can be targeted by cereblon E3 ubiquitin ligase-recruiting heterobifunctional degraders (dBRD9), achieving 10- to 100-fold enhanced potency over parental BRD9 bromodomain ligands in AML models.\",\n      \"method\": \"Heterobifunctional PROTAC design, cellular degradation assays, MS proteomics\",\n      \"journal\": \"Angewandte Chemie (International ed. in English)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — iterative chemical design with cellular validation, MS confirmation of degradation selectivity\",\n      \"pmids\": [\"28418626\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"BRD9 contains a bromodomain that functions as an acetyl-lysine reader; I-BRD9 is a selective inhibitor (>700-fold selectivity over BET family, >200-fold over BRD7) identified by structure-based design that displaces BRD9 from chromatin and regulates oncology and immune response gene networks.\",\n      \"method\": \"Structure-based drug design, selectivity profiling across bromodomain panel, cellular chromatin displacement assays, gene expression profiling in Kasumi-1 cells\",\n      \"journal\": \"Journal of medicinal chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — crystal structure-guided design, validated with functional cellular assays and broad selectivity panel\",\n      \"pmids\": [\"25856009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"BRD9 defines a non-canonical BAF complex (GBAF) in mouse embryonic stem cells together with GLTSCR1 or GLTSCR1L, which is distinct from the canonical esBAF complex; GBAF co-localizes with regulators of naive pluripotency and BRD9 interacts with BRD4 in a bromodomain-dependent fashion to recruit GBAF to chromatin.\",\n      \"method\": \"Co-immunoprecipitation, ChIP-seq, genome-wide localization, inhibitor treatments, pluripotency functional assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP, genome-wide ChIP-seq, bromodomain-dependent interaction validated pharmacologically\",\n      \"pmids\": [\"30510198\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BRD9 defines a SWI/SNF sub-complex lacking SMARCB1; SMARCB1 loss causes increased BRD9 incorporation into SWI/SNF; while BRD9's bromodomain is dispensable, its DUF3512 domain is essential for SWI/SNF complex integrity in the absence of SMARCB1, creating a specific vulnerability in SMARCB1-mutant rhabdoid tumors.\",\n      \"method\": \"Genome-wide CRISPR-Cas9 screen, domain deletion/mutation analysis, ChIP-seq, co-immunoprecipitation\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — genome-wide CRISPR screen, domain mutagenesis, ChIP-seq, Co-IP with multiple orthogonal methods\",\n      \"pmids\": [\"31015438\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"BRD9, as a subunit of the SWI-SNF chromatin remodeling complex, is required in AML cells to sustain MYC transcription; a bromodomain-swap resistance allele of BRD9 retains SWI/SNF functionality despite altered bromodomain pocket, establishing on-target BRD9 bromodomain engagement as the antiproliferative mechanism.\",\n      \"method\": \"Bromodomain-swap genetic engineering (allelic replacement), small-molecule inhibitor series, antiproliferative assays, MYC transcription measurement\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — engineered resistance allele confirms on-target mechanism, combined with chemical probe and differentiation assays\",\n      \"pmids\": [\"27376689\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Following DNA damage, the BRD9 bromodomain binds acetylated K515 on RAD54 and facilitates RAD54's interaction with RAD51, which is essential for homologous recombination (HR)-mediated DNA double-strand break repair.\",\n      \"method\": \"Co-immunoprecipitation, pulldown assays, HR reporter assays, BRD9 inhibitor (I-BRD9) treatment, RAD54 acetylation mapping\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — specific acetyl-lysine binding identified, Co-IP of BRD9-RAD54-RAD51 complex, functional HR assays, replicated with inhibitor and genetic depletion\",\n      \"pmids\": [\"32457312\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BRD9 interacts with androgen receptor (AR) and CTCF, and the GBAF (ncBAF) complex exhibits overlapping genome localization with BET proteins to coordinate SWI/SNF-BET cooperation in AR-dependent gene expression in prostate cancer.\",\n      \"method\": \"Co-immunoprecipitation, ChIP-seq, BRD9 inhibitor/degrader treatment, xenograft tumor growth assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP of BRD9 with AR and CTCF, ChIP-seq genome localization overlap, functional loss-of-function with defined transcriptional phenotype\",\n      \"pmids\": [\"33355184\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BRD9, as a subunit of the ncBAF complex, regulates interferon-stimulated genes (ISGs) in macrophages; BRD9 and BRD4 are cobound at ISG promoters and co-recruited upon endotoxin stimulation along with STAT1, STAT2, and IRF9 (ISGF3 complex); BRD9 inhibition or degradation reduces STAT1/STAT2/IRF9 binding at these loci.\",\n      \"method\": \"ChIP-seq, BRD9 inhibitor (BRD9i) and degrader (dBRD9) treatment, gene expression analysis, transcription factor binding assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-seq genome-wide with orthogonal pharmacological and degrader approaches, STAT factor binding quantified\",\n      \"pmids\": [\"34983841\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BRD9 colocalizes with GR at a subset of genomic binding sites in macrophages; depletion of BRD9 enhances GR occupancy at inflammatory-related genes, thereby potentiating GR-induced transcriptional repression, identifying BRD9 as a genomic antagonist of GR.\",\n      \"method\": \"ChIP-seq, BRD9 inhibition, degradation, and genetic deletion in macrophages, GR occupancy analysis, inflammatory gene expression profiling\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide ChIP-seq with multiple orthogonal BRD9 depletion methods, in vivo validation in HFD mouse model\",\n      \"pmids\": [\"34446564\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Binding of a 9H-purine scaffold ligand to the BRD9 bromodomain causes an unprecedented rearrangement of residues forming the acetyllysine recognition site (induced-fit pocket), and displaces BRD9 from chromatin without affecting BRD4/histone complexes.\",\n      \"method\": \"Crystal structure determination, bioluminescence proximity assay, structure-based iterative design\",\n      \"journal\": \"Journal of medicinal chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with induced-fit mechanism validated by functional chromatin displacement assay\",\n      \"pmids\": [\"25703523\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BRD9 binds enhancer regions in a cell-type-specific manner in AML cells and sustains a STAT5 signaling pathway by regulating SOCS3 expression levels, which is required for leukemia cell survival.\",\n      \"method\": \"ChIP-seq, siRNA knockdown, gene expression profiling, apoptosis assays in AML cells and primary blasts\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-seq localization data with functional loss-of-function; single lab\",\n      \"pmids\": [\"31000698\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In clear cell RCC, SOX17 recruits BRD9 to de novo super enhancers associated with oncogenic genes (CCND1, VEGFR2, CDC20, SRC, MAPK6); BRD9 mRNA is stabilized via FTO-mediated m6A demethylation in HIF2α-low ccRCC.\",\n      \"method\": \"CRISPR-Cas9 knockout screen in vivo, RNA-seq, ChIP-seq, m6A analysis\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR screen plus ChIP-seq plus RNA-seq; SOX17-BRD9 recruitment shown by ChIP but direct interaction not biochemically confirmed\",\n      \"pmids\": [\"34586831\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"BRD9 forms a complex with SMAD2/3, BRD4, β-CATENIN, and P300 to regulate TGF-β/Nodal/Activin and Wnt signaling pathways by controlling H3K27ac deposition on pluripotency and differentiation genes in human ESCs.\",\n      \"method\": \"Co-immunoprecipitation, ChIP-seq, H3K27ac profiling, BRD9 depletion/inhibition, rescue experiments with pathway ligands\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP of multi-protein complex, ChIP-seq, functional epistasis with pathway ligand rescue; single lab\",\n      \"pmids\": [\"37870468\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"BRD9 inhibition disrupts enhancer-promoter looping and transcription of stemness genes in pancreatic cancer stem-like cells, and mechanistically cooperates with TGF-β/Activin-SMAD2/3 signaling to orchestrate CSC stemness.\",\n      \"method\": \"Small molecule epigenetic screen, genetic ablation, 3D chromatin looping analysis, patient-derived xenografts\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — chromatin looping assays, genetic ablation, PDX models; single lab\",\n      \"pmids\": [\"37739089\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CCAR2 acetylation by sulforaphane creates a binding site recognized by BRD9 (and BET family members); BRD9 acts as an acetyl reader of acetylated CCAR2, revealed by protein domain arrays and pull-down assays, contributing to a BET/BRD9 acetyl switch governing Wnt coactivator functions.\",\n      \"method\": \"Protein domain arrays, pull-down assays, Co-IP, BRD9 inhibitor treatment (JQ1/sulforaphane combination), colorectal cancer model\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — pulldown and domain array identification of acetyl-reader function; supported by phenotypic data in vivo\",\n      \"pmids\": [\"30643017\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"BRD9 interacts with transcription factor FOXP1, activating Stat1 transcription and IFN-β signaling, thereby suppressing osteoclastogenesis through a negative feedback mechanism on RANKL-induced osteoclast differentiation.\",\n      \"method\": \"Co-immunoprecipitation, ChIP assays, myeloid-specific Brd9 conditional knockout mouse model, osteoclast differentiation assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP of BRD9-FOXP1, ChIP at Stat1 locus, in vivo conditional KO with bone phenotype, multiple orthogonal methods\",\n      \"pmids\": [\"36918560\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"BRD9 loss in hematopoietic stem cells enhances chromatin accessibility and significantly colocalizes with CTCF; BRD9 loss augments CTCF chromatin recruitment, leading to altered chromatin state and expression of myeloid-related genes within intact topologically associating domains.\",\n      \"method\": \"ChIP-seq, ATAC-seq, RNA-seq, Hi-C, conditional Brd9 knockout mouse model\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multi-omics (ChIP-seq, ATAC-seq, Hi-C), in vivo KO with defined hematopoietic phenotypes\",\n      \"pmids\": [\"38102116\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BRD9 inhibition downregulates fibroblast-related genes and decreases chromatin accessibility at somatic enhancers during human cell reprogramming; BRD9 maintains expression of transcriptional regulators MN1 and ZBTB38 that impede reprogramming, acting as a barrier to pluripotency.\",\n      \"method\": \"Genetic and chemical inhibition of BRD9, ATAC-seq, gene expression profiling, reprogramming efficiency assays\",\n      \"journal\": \"Stem cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ATAC-seq and functional reprogramming assays; single lab, specific downstream targets identified\",\n      \"pmids\": [\"36332631\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"BRD9 plays a pivotal role in recruiting BRD2 and BRD4 to chromatin through direct interactions, preventing R-loop formation during transcription; BRD9 depletion reduces BRD2/BRD4 occupancy at R-loop-prone sites, promoting R-loop accumulation, transcription-replication conflict, and DNA damage in leukemia cells.\",\n      \"method\": \"Co-immunoprecipitation, ChIP-seq, R-loop detection (DRIP-seq), PROTAC-based BRD9 degradation, proliferation and differentiation assays\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct BRD9-BRD2/BRD4 interaction by Co-IP, R-loop mapping genome-wide, multiple depletion strategies with convergent phenotypes\",\n      \"pmids\": [\"40613709\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"BRD9 functions as a reader of methylated arginine-391 (R391) of AKT1 through an aromatic cage in its bromodomain, unexpectedly extending its reader function beyond acetyl-lysine; BRD9 and AKT co-regulate transcription through EZH2-mediated H3K27 methylation.\",\n      \"method\": \"Biochemical binding assays, bromodomain mutational analysis, RNA-seq, in vivo tumor growth assays, synergy assays with EZH2 inhibitors\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — novel reader function identified with direct binding assays, aromatic cage mutagenesis, functional downstream validation\",\n      \"pmids\": [\"40279411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"BRD9 binds to HIV-1 LTR promoter and competes with HIV-1 Tat protein for binding to the HIV-1 genome, functioning as an HIV-1 latency regulator; BRD9 inhibition synergizes with BRD4 inhibition in inducing HIV-1 production.\",\n      \"method\": \"CUT&RUN DNA sequencing, transcriptomics, BRD9 inhibition/knockdown/degradation in T cell lines and primary CD4+ T cells, competition binding assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — CUT&RUN mapping of BRD9 at LTR, competition with Tat, multiple BRD9 depletion strategies; single lab\",\n      \"pmids\": [\"40402245\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Ultra-rare truncating loss-of-function variants in BRD9 impair IFN-stimulated gene expression and antiviral activity, establishing BRD9 as functionally required for full type I interferon signaling; full-length BRD9 but not truncated forms restore IFN-dependent antiviral response.\",\n      \"method\": \"BRD9 knockout and reconstitution model, functional IFN-stimulated gene expression assays, viral replication assays\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reconstitution of KO cells with wild-type vs. truncated variants, functional antiviral readout; single lab\",\n      \"pmids\": [\"36100643\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BRD9 epigenetically coordinates H3K27ac modifications on promoter regions of glycolysis genes ENO2 and ALDOC, inducing enhanced glycolysis activity in colon adenocarcinoma cells.\",\n      \"method\": \"ChIP assay for H3K27ac at ENO2/ALDOC promoters, Seahorse metabolic flux analysis, BRD9 knockdown/overexpression, in vivo xenograft model\",\n      \"journal\": \"Cancer medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-qPCR for H3K27ac at specific loci, metabolic functional assays; single lab\",\n      \"pmids\": [\"35778964\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"BRD9 inhibits p53 nuclear translocation via direct binding, subsequently activating E2F transcription factors; E2F1 directly binds and transactivates the BRD9 promoter, establishing a positive BRD9-p53-E2F1 feedback loop in gastric cancer.\",\n      \"method\": \"Co-immunoprecipitation, subcellular fractionation, luciferase reporter assays, RNA sequencing\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP of BRD9-p53, fractionation showing p53 nuclear exclusion, luciferase reporter for E2F1-BRD9 promoter interaction; single lab\",\n      \"pmids\": [\"41039535\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BRD9 ncBAF complex regulates AML transcription through H3K27ac sensing by BRD9 bromodomain; BRD9 bromodomain activity maintains chromatin accessibility at gene promoters and distal enhancers at GATA, ETS, and AP-1 motifs, repressing myeloid maturation factors and tumor suppressor genes.\",\n      \"method\": \"BRD9 bromodomain inhibition, nascent transcription assays (TT-seq), ATAC-seq, CUT&RUN, in five AML cell lines\",\n      \"journal\": \"Cancer research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multi-omics approach in multiple AML cell lines; bromodomain-specific inhibition separates reader from scaffold function\",\n      \"pmids\": [\"38126767\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"BRD9 selectively recruits DCAF16 E3 ligase via a reversible covalent interaction at DCAF16 Cys58, facilitated by ternary complex formation with BRD9, enabling targeted protein degradation (molecular glue mechanism); BRD9 degradation is achieved in vivo after oral dosing.\",\n      \"method\": \"Co-immunoprecipitation-mass spectrometry, mutagenesis of DCAF16 Cys58, ternary complex analysis, in vivo xenograft mouse model with oral dosing\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — Co-IP-MS confirming selective DCAF16 recruitment, cysteine mutagenesis validation, in vivo proof of concept\",\n      \"pmids\": [\"41145412\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"BRD9 loss in SF3B1-mutant hematopoiesis enhances CTCF occupancy at the ALOX5 locus boundary via aberrant chromatin loop formation (revealed by Hi-C), driving transcriptional activation of ALOX5 and increased lipid peroxidation/ferroptosis susceptibility.\",\n      \"method\": \"RNA-seq, ChIP-seq, Hi-C, BODIPY-C11 lipid peroxidation assay, BRD9 depletion mouse models\",\n      \"journal\": \"International journal of hematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-seq plus Hi-C mechanistic link, functional ferroptosis assay; single lab\",\n      \"pmids\": [\"41219678\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"BRD9's bromodomain reads lactate-induced H3K18 lactylation (H3K18la) with transient affinity through its conserved acetyl-lysine pocket (distinct from stable H3K18ac binding), dynamically recruiting ncBAF to active enhancers/promoters to drive oncogenic transcription in hepatocellular carcinoma.\",\n      \"method\": \"NMR structural analysis, biophysical binding assays, multi-omics (ATAC-seq, ChIP-seq, RNA-seq), BRD9 targeting experiments in HCC\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR structural characterization of H3K18la binding plus multi-omics functional validation; novel PTM reader activity\",\n      \"pmids\": [\"41792243\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PPARα interacts with ncBAF via BRD9; BRD9 negatively regulates PPARα-mediated transactivation of fatty acid oxidation genes (including CPT1A) by restricting chromatin accessibility at PPRE elements; BRD9 inhibition enhances PPARα binding to CPT1A PPRE.\",\n      \"method\": \"Glycerol sedimentation assay, co-immunoprecipitation, pull-down assays, ChIP-qPCR, FAIRE-qPCR, BRD9 inhibitor (BI-9564) treatment in HepG2 and primary hepatocytes, in vivo mouse model\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct PPARα-BRD9 interaction by Co-IP and pulldown, ChIP and FAIRE chromatin accessibility assays, in vivo lipid phenotype\",\n      \"pmids\": [\"40780491\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"BRD9 binds RELA and potentiates expression of downstream antiviral genes in glioblastoma, creating resistance to oncolytic herpes simplex virus; BRD9 knockout or inhibition suppresses antiviral gene expression and enhances oncolytic virus efficacy.\",\n      \"method\": \"CRISPR screening, co-immunoprecipitation (BRD9-RELA), transcriptomic analysis, in vitro and in vivo GBM models\",\n      \"journal\": \"Cell reports. Medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR screen plus Co-IP of BRD9-RELA, functional oncolytic virus assay; single lab\",\n      \"pmids\": [\"40744020\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BRD9 interacts with FOXP1 to regulate CST1 expression and downstream PI3K/AKT signaling in gallbladder cancer, as demonstrated by ChIP-qPCR showing BRD9 occupancy at CST1 promoter and co-interaction with FOXP1.\",\n      \"method\": \"siRNA knockdown, ChIP-qPCR, RNA sequencing, in vivo xenograft model, FOXP1-BRD9 interaction assay\",\n      \"journal\": \"Gene therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — ChIP-qPCR at specific locus and FOXP1 interaction; single lab, limited mechanistic depth\",\n      \"pmids\": [\"39306629\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BRD9 is found in the SWI/SNF complex bound to the MYC super-enhancer locus in PIK3CA/KRAS double-mutant breast epithelial cells; small molecule inhibition of BRD9 reduces MYC transcript levels and anchorage-independent growth dependent on BRD9 expression.\",\n      \"method\": \"ChIP at MYC super-enhancer, CRISPR-Cas9 BRD9 manipulation, BRD9 inhibitor treatment, anchorage-independent growth assays\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP at MYC enhancer, genetic CRISPR validation, functional epistasis with PIK3CA; single lab\",\n      \"pmids\": [\"31652979\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BRD9 promotes MYC target gene expression in multiple myeloma by predominantly occupying promoter regions of ribosome biogenesis genes and cooperating with BRD4 to enhance MYC transcriptional function.\",\n      \"method\": \"shRNA knockdown, PROTAC degrader (dBRD9-A), ChIP-seq at ribosome biogenesis gene promoters, RNA-seq, in vivo xenograft\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-seq occupancy data, genetic and pharmacological depletion; BRD9-BRD4 cooperation at MYC targets supported but BRD4 interaction not directly biochemically shown\",\n      \"pmids\": [\"36780189\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Pharmacological BRD9 inhibition in macrophages disrupts BRD9 and SMARCA4 occupancy at melanocyte-specific chromatin loci, repressing pigmentation-specific gene expression and melanin synthesis.\",\n      \"method\": \"ChIP assays for BRD9 and SMARCA4, iBRD9 treatment, BRD9 depletion, gene expression profiling in melanoblasts and melanocytes\",\n      \"journal\": \"Pigment cell & melanoma research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP showing BRD9/SMARCA4 co-occupancy at melanocyte loci, confirmed by genetic depletion; single lab\",\n      \"pmids\": [\"36112085\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BRD9 is the defining bromodomain-containing subunit of the non-canonical BAF (ncBAF/GBAF) SWI/SNF chromatin remodeling complex, where its bromodomain reads acetylated lysines (and unexpectedly methylated arginine and lactylated lysine) on histones and non-histone proteins to recruit ncBAF to chromatin; its DUF3512 domain is essential for complex integrity, while it interacts with BRD4, CTCF, SMAD2/3, androgen receptor, GR, p53, FOXP1, RAD54, RELA, and PPARα to regulate gene expression programs controlling pluripotency, hematopoiesis, immune responses, DNA repair via homologous recombination, and oncogenic transcription in multiple cancer contexts.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"BRD9 is the defining bromodomain-containing subunit of the non-canonical BAF (ncBAF/GBAF) chromatin remodeling complex, where it functions as a multivalent epigenetic reader that recruits SWI/SNF remodeling activity to specific genomic loci in a context-dependent manner to regulate gene expression programs governing pluripotency, hematopoiesis, immune signaling, DNA repair, and metabolism. Its bromodomain reads acetylated lysines on histones (H3K27ac, H3K18ac) and non-histone proteins (RAD54 K515ac, CCAR2), and also recognizes methylated arginine (AKT1 R391me) and lactylated lysine (H3K18la), while its DUF3512 domain is essential for ncBAF complex integrity [PMID:30510198, PMID:31015438, PMID:32457312, PMID:40279411, PMID:41792243]. BRD9 physically interacts with BRD4 and BRD2 to coordinate BET-SWI/SNF cooperation at promoters and enhancers, and partners with transcription factors including CTCF, androgen receptor, GR, SMAD2/3, FOXP1, RELA, PPARα, and p53 to direct locus-specific chromatin accessibility and transcriptional output [PMID:33355184, PMID:34983841, PMID:34446564, PMID:36918560, PMID:37870468, PMID:40780491, PMID:40613709]. BRD9 loss increases CTCF chromatin occupancy and alters three-dimensional chromatin architecture within topologically associating domains, and disrupts R-loop resolution at transcription-replication conflict sites, linking its function to genome stability and myeloid differentiation [PMID:38102116, PMID:40613709, PMID:41219678].\",\n  \"teleology\": [\n    {\n      \"year\": 2015,\n      \"claim\": \"Establishing that BRD9 contains a druggable acetyl-lysine-reading bromodomain with unique structural plasticity resolved whether this domain could be selectively targeted apart from the closely related BRD7 and BET family members.\",\n      \"evidence\": \"Crystal structures of BRD9 bromodomain with ligands revealed an induced-fit rearrangement of the acetyl-lysine pocket, and I-BRD9 achieved >700-fold selectivity over BET and >200-fold over BRD7, displacing BRD9 from chromatin in Kasumi-1 AML cells\",\n      \"pmids\": [\"25703523\", \"25856009\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No histone mark specificity defined at this stage\", \"Cellular targets of BRD9 bromodomain beyond generic chromatin association unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrating that BRD9's bromodomain engagement sustains MYC transcription in AML cells established the first functional requirement for BRD9 reader activity in an oncogenic transcriptional program.\",\n      \"evidence\": \"Bromodomain-swap resistance allele in AML cells confirmed that antiproliferative effects of BRD9 inhibitors are on-target and linked to MYC transcript downregulation\",\n      \"pmids\": [\"27376689\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which SWI/SNF sub-complex BRD9 belongs to was not yet defined\", \"Mechanism by which BRD9 is recruited to MYC locus not resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identifying BRD9 as the defining subunit of a non-canonical BAF complex (ncBAF/GBAF) containing GLTSCR1/GLTSCR1L resolved the composition of a previously uncharacterized SWI/SNF variant and revealed its BRD4-dependent chromatin recruitment at naive pluripotency loci.\",\n      \"evidence\": \"Reciprocal Co-IP, ChIP-seq, and bromodomain inhibitor treatments in mouse ESCs showed GBAF is distinct from esBAF; BRD9 interacts with BRD4 in a bromodomain-dependent manner\",\n      \"pmids\": [\"30510198\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BRD9-BRD4 interaction is direct or mediated through shared chromatin marks\", \"Structural basis of GLTSCR1 incorporation into ncBAF\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Establishing that the DUF3512 domain (not the bromodomain) is essential for SWI/SNF complex integrity in SMARCB1-mutant cancers revealed a synthetic lethal vulnerability and separated BRD9's scaffolding from its reader function.\",\n      \"evidence\": \"CRISPR screen and domain deletion analysis in rhabdoid tumor cells showed SMARCB1 loss increases BRD9 incorporation and creates BRD9 dependency through DUF3512\",\n      \"pmids\": [\"31015438\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of DUF3512-mediated complex assembly unknown\", \"Whether DUF3512 dependency extends to other SMARCB1-deficient tumor types\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrating BRD9 as an acetyl-reader of non-histone substrates (CCAR2) broadened its recognition repertoire beyond histone tails and implicated it in Wnt coactivator regulation.\",\n      \"evidence\": \"Protein domain arrays and pull-down assays showed BRD9 bromodomain binds acetylated CCAR2, contributing to a BET/BRD9 acetyl switch in colorectal cancer\",\n      \"pmids\": [\"30643017\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct binding affinity not quantified\", \"Specificity of BRD9 versus BET recognition of CCAR2 acetylation unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identifying BRD9 as a reader of acetylated RAD54 that facilitates RAD54-RAD51 interaction established a direct role for BRD9 in homologous recombination DNA repair, independent of its canonical chromatin remodeling function.\",\n      \"evidence\": \"Co-IP, pulldown, and HR reporter assays showed BRD9 bromodomain binds RAD54 K515ac and is required for RAD54-RAD51 complex formation after DNA damage\",\n      \"pmids\": [\"32457312\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BRD9-RAD54 interaction occurs in the context of ncBAF or as a free subunit\", \"No structural model of BRD9-RAD54 interaction\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showing that BRD9/ncBAF interacts with androgen receptor and CTCF and co-localizes with BET proteins genome-wide in prostate cancer linked ncBAF to steroid hormone-driven transcription.\",\n      \"evidence\": \"Co-IP of BRD9 with AR and CTCF, ChIP-seq overlap with BET, and BRD9 degrader/inhibitor treatment reducing AR target gene expression and xenograft tumor growth\",\n      \"pmids\": [\"33355184\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BRD9 directly bridges AR and BRD4 or they are independently recruited\", \"Contribution of CTCF to BRD9-AR cooperation not dissected\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrating that BRD9 depletion enhances GR occupancy at inflammatory gene loci established BRD9 as a genomic antagonist of glucocorticoid receptor, revealing a competition model for transcription factor access at shared sites.\",\n      \"evidence\": \"ChIP-seq with BRD9 inhibition/degradation/knockout in macrophages showed increased GR binding at inflammatory genes; validated in vivo in high-fat diet mouse model\",\n      \"pmids\": [\"34446564\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BRD9-GR antagonism is direct or mediated through chromatin state changes\", \"Mechanism by which ncBAF limits GR accessibility not resolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Establishing that BRD9 and BRD4 are co-recruited to ISG promoters with ISGF3 upon endotoxin stimulation, and that BRD9 loss reduces STAT1/2/IRF9 binding, defined BRD9 as a chromatin prerequisite for interferon-stimulated gene activation in innate immunity.\",\n      \"evidence\": \"ChIP-seq in macrophages with BRD9 inhibitor and dBRD9 degrader showed diminished ISGF3 component occupancy at ISG loci; complemented by truncation variants failing to rescue IFN responses\",\n      \"pmids\": [\"34983841\", \"36100643\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BRD9 directly recruits ISGF3 or remodels chromatin to permit ISGF3 binding\", \"Contribution of ncBAF ATPase activity versus BRD9 reader activity not separated\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identifying BRD9 in a complex with SMAD2/3, BRD4, β-catenin, and P300 at pluripotency genes, and showing BRD9 mediates enhancer-promoter looping for stemness genes, unified its roles in TGF-β/Wnt signaling and 3D chromatin architecture.\",\n      \"evidence\": \"Co-IP of multi-protein complex in hESCs, ChIP-seq for H3K27ac, rescue with pathway ligands; chromatin looping analysis in pancreatic cancer stem cells\",\n      \"pmids\": [\"37870468\", \"37739089\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Stoichiometry of the BRD9-SMAD2/3-BRD4-P300 complex not defined\", \"Whether BRD9 directly mediates looping or acts indirectly through cohesin/CTCF\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrating that BRD9 loss in hematopoietic stem cells increases CTCF chromatin occupancy and alters chromatin architecture within TADs revealed BRD9 as a modulator of 3D genome organization controlling myeloid differentiation.\",\n      \"evidence\": \"Multi-omics (ChIP-seq, ATAC-seq, Hi-C, RNA-seq) in conditional Brd9 knockout mice showed enhanced CTCF binding and myeloid gene activation\",\n      \"pmids\": [\"38102116\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ncBAF mechanistically limits CTCF occupancy (direct competition vs. nucleosome positioning)\", \"Whether altered TAD structure is a cause or consequence of differentiation changes\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Discovering that BRD9 reads methylated arginine on AKT1 (R391me) through an aromatic cage in its bromodomain fundamentally expanded the recognition code beyond acetyl-lysine to include arginine methylation marks.\",\n      \"evidence\": \"Biochemical binding assays and aromatic cage mutagenesis showed direct BRD9 bromodomain binding to AKT1 R391me; functional cooperation with EZH2-mediated H3K27me shown by synergy assays\",\n      \"pmids\": [\"40279411\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of arginine methylation reading versus acetyl-lysine reading not resolved at atomic level\", \"Breadth of methylarginine substrates recognized by BRD9 unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Showing that BRD9 recruits BRD2/BRD4 to chromatin and prevents R-loop accumulation at transcription-replication conflict sites established a genome stability function beyond homologous recombination.\",\n      \"evidence\": \"Co-IP, ChIP-seq, and DRIP-seq in leukemia cells showed BRD9 depletion reduces BRD2/BRD4 occupancy at R-loop-prone sites, causing R-loop accumulation and DNA damage\",\n      \"pmids\": [\"40613709\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether R-loop resolution requires ncBAF ATPase activity or only BRD9-BET recruitment\", \"No reconstituted system demonstrating BRD9-dependent R-loop prevention\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Identifying lactylated H3K18 (H3K18la) as a physiologically relevant mark read by BRD9's bromodomain with transient affinity expanded the epigenetic reader code to include metabolic signaling through lactate-driven histone modification.\",\n      \"evidence\": \"NMR structural analysis showed H3K18la binds the conserved acetyl-lysine pocket with lower affinity than H3K18ac; multi-omics in hepatocellular carcinoma confirmed dynamic ncBAF recruitment to lactylation-marked enhancers\",\n      \"pmids\": [\"41792243\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether transient H3K18la reading confers distinct transcriptional kinetics compared to stable H3K18ac reading\", \"In vivo validation of lactylation-dependent BRD9 recruitment in non-cancer contexts\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural basis of how BRD9's bromodomain discriminates among acetylated, methylated, and lactylated marks, and how the DUF3512 domain scaffolds the ncBAF complex, remain unresolved at atomic resolution.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No full-length BRD9 structure or cryo-EM structure of BRD9 within ncBAF\", \"Mechanism by which BRD9 limits CTCF occupancy not biochemically reconstituted\", \"Whether BRD9's non-histone reader functions operate within or outside the ncBAF complex context\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [2, 6, 10, 15, 20, 25, 28]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [9, 24, 29]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [5, 8, 13, 16, 23]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [3, 4, 7, 8, 17, 25]},\n      {\"term_id\": \"GO:0005694\", \"supporting_discovery_ids\": [3, 4, 17, 19, 25, 28]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [3, 4, 17, 25, 28]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [5, 8, 13, 16, 23, 29]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [6, 19]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [8, 9, 22, 30]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [11, 13, 14, 24, 29]}\n    ],\n    \"complexes\": [\n      \"ncBAF (GBAF) SWI/SNF complex\"\n    ],\n    \"partners\": [\n      \"BRD4\",\n      \"CTCF\",\n      \"SMARCA4\",\n      \"GLTSCR1\",\n      \"RAD54\",\n      \"FOXP1\",\n      \"RELA\",\n      \"PPARA\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}